Erlotinib May Enhance Cervical Cancer SurvivalErlotinib May Enhance Cervical Cancer Survival
The targeted antitumor agent erlotinib added to standard treatment is showing promise in prolonging survival for patients with locally advanced cervical cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 12, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Targeted therapy with erlotinib may prolong survival of patients with cervical cancer
A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.Nearly half a million new cases of cervical cancer are reported worldwide each year, making it the third most common cancer among females. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 10, 2014 Category: Consumer Health News Tags: Cervical Cancer / HPV Vaccine Source Type: news
Targeted drug may prolong survival of patients with cervical cancer
(Wiley) A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 10, 2014 Category: Global & Universal Source Type: news
NICE set to take away standard of care for over 1000 lung cancer patients
The National Institute for Health and Care Excellence (NICE) has recommended that relapsed (second line) non-small cell lung cancer (NSCLC) patients no longer have access to cancer pill Tarceva® (erlotinib) because it does not meet their criteria for clinical and cost-effectiveness.( (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 13, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Legislation & regulation Oncology Latest News Source Type: news
Hundreds of cancer patients in England and Wales to be denied life-prolonging drug
The National Institute for Health and Care Excellence has changed its guidance on Tarceva meaning it will no longer be available to patients. (Source: the Mail online | Health)
Source: the Mail online | Health - February 5, 2014 Category: Consumer Health News Source Type: news
Everolimus fails to boost advanced NSCLC response
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 28, 2014 Category: Cancer & Oncology Source Type: news
Everolimus fails to boost advanced NSCLC response
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - January 28, 2014 Category: Cancer & Oncology Source Type: news
Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - December 16, 2013 Category: Cancer & Oncology Source Type: news
Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 16, 2013 Category: Cancer & Oncology Source Type: news
Investigational c-Met inhibitor shows early promise in NSCLC
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 3, 2013 Category: Cancer & Oncology Source Type: news
Investigational c-Met inhibitor shows early promise in NSCLC
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - December 3, 2013 Category: Cancer & Oncology Source Type: news
Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy
Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 4, 2013 Category: Cancer & Oncology Source Type: news
Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy
Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - November 4, 2013 Category: Cancer & Oncology Source Type: news
New Approach to NSCLC Therapy: Targeting MET Activation New Approach to NSCLC Therapy: Targeting MET Activation
Results from a subset of patients show improved outcomes when a MEK inhibitor is used with erlotinib in MEK-positive non-small cell lung cancer (NSCLC). Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 10, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Two-Drug Maintenance May Not Pan Out in NSCLC (CME/CE)
(MedPage Today) -- Combination maintenance therapy with erlotinib (Tarceva) and bevacizumab (Avastin) modestly delayed progression but not death in advanced non-small cell lung cancer, the ATLAS trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 7, 2013 Category: Hematology Source Type: news
